Business Wire

DIA

30.1.2024 10:01:28 CET | Business Wire | Press release

Share
DIA Europe 2024 to Confront Sustainability, Innovation, and Collaboration in Healthcare

DIA, a global organization of life sciences professionals, will emphasize how collaboration and innovation can support sustainability in healthcare at DIA Europe 2024, to be held March 12-14 at Square Brussels Convention Centre in Brussels.

DIA Europe, the largest and most forward-looking neutral healthcare conference on the continent, is the only event that gives representatives from the European Commission, the European Medicines Agency (EMA), the World Health Organization (WHO), the Heads of Medicines Agencies (HMA), national competent authorities, healthcare professionals, and patient populations the opportunity to come together to shape key policy decisions.

Now in its 36th year, DIA Europe will feature discussions on the environmental footprint of pharmaceuticals and drug development. Panelists will explore optimal sustainability practices with more than 250 guest speakers across 11 rich content tracks that comprise 100-plus sessions, including much-anticipated "DIAmond sessions" and town halls. They will also participate in collaboration hubs, showcases, and workshops designed to drive change and innovative thinking.

"Sustainability is one of the defining challenges in healthcare today," said Ania Mitan, DIA's Senior Vice President and Managing Director, EMEA and India. "No organization can tackle it alone, but through open dialogue, partnership across industry, government, and academia, and listening to the patient's perspective, we can drive real progress. Learning from each other will empower us to develop new approaches that benefit patients, society, and our planet."

Attendees will hear from more than 25 EMA executives, including Emer Cooke, the Executive Director of the EMA and the Chair of the International Coalition of Medicines Regulatory Authorities (ICMRA); Martin Harvey Allchurch, the EMA's Head of International Affairs; and Dr. Peter Arlett, the EMA's Head of Data Analytics and Methods Task Force.

Leda Stott, a Senior Research Fellow at the Innovation and Technology for Development Centre at the Technical University of Madrid and an authority on multi-stakeholder collaboration; Veronique Toully, the Global Head of Sustainability, Corporate Affairs and Risks at UCB; and Dr. Glenn Wells, Chief Partnerships Officer at the Medicines and Healthcare Products Regulatory Agency (MHRA), will deliver a keynote address that examines healthcare's most pressing sustainability challenges.

Other can't-miss sessions include:

— "EU Regulatory Town Hall: The New Pharmaceutical Legislation": Explore how we are increasing availability and access to novel healthcare solutions.
— "Digital Transformation in the EU Regulatory Space": Discuss how Europe is building the foundations for its digital transformation in the regulatory space for the next 10 years.
— "Complexity: Interplay and Interface of Different Legislations": Learn how we can drive medicine research, development, and manufacturing amid an increasingly complicated landscape of EU policies and regulations.

Three new content tracks this year will cover emerging trends in healthcare: Artificial Intelligence, Data Science, and Real-World Evidence; Innovative Therapies, Precision Medicine, and Diagnostics; and International Collaboration and Regional Updates.

DIA is celebrating 60 years of bringing together leading minds to foster innovation, collaboration, and advancement in global healthcare.

At DIA Europe, everyone meets on equal terms. To register to attend as a participant or media member, visit https://www.diaglobal.org/Flagship/DIA-Europe-2024.

About DIA

DIA is a leading global life science membership association that drives collaboration in drug, device, and diagnostics development in pursuit of a healthier world. Founded in 1964 with headquarters in Washington, D.C., and offices in Europe and Asia, DIA provides unparalleled networking opportunities, educational resources, scientific research publications, and professional development programs to members in more than 80 countries.

Learn more at DIAglobal.org, and connect with DIA on LinkedIn, Facebook, X (Twitter), and Instagram.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240130133798/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

AV Access Presents eShare W90: A 4K Wireless Conferencing System for Smarter Hybrid Meetings at ISE 2026 in Barcelona28.1.2026 09:00:00 CET | Press release

AV Access proudly announces its participation in ISE 2026, one of the world’s leading AV and systems integration exhibitions. From February 3-6 at the Fira de Barcelona, Gran Via, the company will showcase its latest solutions designed to improve collaboration, enhance entertainment, and boost workplace productivity. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260128178621/en/ The eShare W90 wireless presentation and conferencing system makes hybrid meetings more secure, more collaborative, and far easier to manage. At Booth 1F110, AV Access will highlight its flagship innovations, including the eShare W90 wireless conferencing system, the plug-and-play 4KIP200 HDMI over IP solution, and the complete iDock series of KVM docking stations—demonstrating its dedication to versatile, high-performance AV technology. Stream, Charge and Share with a Single USB-C Cable At the heart of the booth is the eShare W90 wireless presentat

SES Extends EGNOS GEO-1 Satellite Service to Power Precise Navigation Across Europe28.1.2026 08:50:00 CET | Press release

The agreement ensures Europe’s satellite-based augmentation continues enhancing navigation for aviation and other critical users and lowering emissions SES, a leading space solutions company, and the European Union Agency for the Space Programme (EUSPA) today announced an extension of the European Geostationary Navigation Overlay Service (EGNOS) GEO-1 satellite service agreement through 2030, with an option to extend until 2032, helping maintain high-precision navigation services for aviation and other critical users across Europe. By improving the accuracy and integrity of satellite positioning signals, EGNOS supports aircraft in landing in low-visibility conditions, as well as planning more efficient routes, reducing fuel burn and CO₂ emissions. At the core of the EGNOS service is Europe’s regional Satellite-Based Augmentation System (SBAS) that improves the accuracy and reliability of Global Navigation Satellite System (GNSS) signals, such as GPS. Beyond aviation, EGNOS supports mar

LTTS Secures Strategic Engineering and R&D Agreement from Global Automotive OEM28.1.2026 08:30:00 CET | Press release

Key win in LTTS’ Mobility Segment across multiple vehicle technology domains L&T Technology Services (BSE: 540115, NSE: LTTS), a global leader in AI, Digital & ER&D Consulting Services, announced that it has secured a significant multi-year engagement in its Mobility segment from a leading automotive OEM. The strategic win further strengthens LTTS’ long-standing partnership with the premium automotive manufacturer and underscores its growing role in supporting next-generation mobility engineering. The engagement encompasses advanced software, connectivity and digital engineering services across multiple vehicle technology domains. LTTS will draw on its global engineering expertise, strong domain knowledge and proven delivery frameworks to support the customer’s evolving product and technology roadmap. This win reinforces LTTS’ comprehensive mobility engineering capabilities, spanning embedded systems, digital platforms, verification and validation, cloud integration, cybersecurity, and

SFI Health™ EMEA Announces the Launch in Poland of Equazen® Forte, Marking a New Chapter in Cognitive Support for Young Adults and Adults28.1.2026 08:00:00 CET | Press release

Equazen® Forte represents a strategic evolution of the brand, extending its clinically researched omega-3 based cognitive support product formulation beyond children to young adults and adults through pharmacies across Poland. SFI Health™ EMEA, the regional entity of SFI Health™, a global leader in natural healthcare, today is pleased to announce the launch of Equazen® Forte in Poland, a new concentrated omega 3 product formulation to be added to the Equazen® range designed to support the normal cognitive performance for young adults and adults. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260127646023/en/ Equazen® Forte: a key milestone in the brand’s long-term development strategy. Equazen® Forte represents a key milestone in the brand’s long-term development strategy. Traditionally recognized as a pediatric brain health expert, Equazen® is now evolving to support consumers across different life stages, addressing changi

Fujirebio Expands Its Neuro Testing Portfolio With the Launch of the Fully Automated Lumipulse® G pTau 217 CSF Assay for Research Use Only28.1.2026 07:07:00 CET | Press release

H.U. Group Holdings Inc. and its wholly-owned subsidiary Fujirebio today announced the availability of the Lumipulse G pTau 217 CSF assay for the fully automated LUMIPULSE® G immunoassay analyzers. This CLEIA (chemiluminescent enzyme immunoassay) assay is available for Research Use Only (RUO) and allows for the quantitative measurement of Tau phosphorylated at threonine 217 (pTau 217) in human cerebrospinal fluid (CSF) within just 35 minutes. Alzheimer’s disease (AD) is characterized by the accumulation of neurofibrillary tangles in the brain, composed of hyperphosphorylated tau, and amyloid plaques, consisting of distinct β-amyloid peptides. CSF pTau217 has emerged as an early biomarker for neuropathological changes associated with AD. This new immunoassay further strengthens Fujirebio’s growing portfolio of neurological biomarkers and reinforces the company’s leading position in the advancement of associated research tools and diagnostics. “By adding pTau 217 CSF to our neuro portfol

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye